JAK2/STAT3/VEGF signalling is activated during angiogenesis in vivo, and tumour suppressor gene, PARK2, was shown to inhibit tumour growth and angiogenesis in vivo by downregulating the JAK2/STAT3/VEGF pathway.76, 91. The gene discussed is VEGFA; the disease is neoplasm.